RxDoctor Payments DataLook up a doctor →

Melissa Wren, NP

Nurse Practitioner · Lees Summit, MONPI 1528482759

Payments from drug & device makers

$10,453in general payments, 2019–2025

Across 555 payments — averaging $18.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Teva Pharmaceuticals USA, Inc.$977
  • Biogen$520
  • Otsuka America Pharmaceutical, Inc.$507
  • E.r. Squibb & Sons, L.L.C.$475
  • EMD Serono, Inc.$398
  • plus $6K from 41 others

What the payments were for

  • Food & beverage$10,33899%
  • Education$1151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,453 in reported general payments places this provider in the 95th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$60,837
Medicare patients
168
Services billed
840

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron15$9,124
Mirtazapine31$976
Carbidopa-LevodopaCarbidopa/Levodopa27$731
Primidone21$680
Galantamine Hbr18$617
Donepezil Hcl58$601
Gabapentin34$515
Trazodone Hcl82$488
Potassium Chloride42$391
Memantine Hcl17$372
Furosemide69$360
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst16$335
Citalopram HbrCitalopram Hydrobromide37$322
Levothyroxine Sodium34$311
Atorvastatin Calcium16$255

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCLevothyroxine Sodium$75$31134 claims
Upsher-smith Laboratories LLCTopiramate$37$23716 claims
PfizerPaxlovid$202$011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Lees Summit

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →